This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Grayston, I. T., Campbell, L. A., Kuo, C.-C., Mordhorst C. H., SaÃkku P., Thom D. H., Wang S. P., 1990, A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR, J. Infect. Dis. 161:618–625.
Beatty, W. L., Morrison, R. P., and Byrne, G. I., 1994, Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis, Microbiol. Rev. 58:686–699.
Muhlestein, J. B., Anderson, J. L., Hammond, E. F., Zhao, L., Trehan, S., Schwobe, E. P., and Carlquist, J. F., 1998, Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model, Circulation 97:633–636.
Constantanides, P., Booth, J., and Carlson, G., 1960, Production of advanced cholesterol atherosclerosis in the rabbit, Arch. Pathol. 70:80–92.
Fong, I. W., Chiu, B., Viira, E., Jang, D., and Mahony, J. B., 2002, Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model, Antimicrob. Agents Chemother. 46:2321–2326.
Rothstein, N. M., Quinn, T. C., Madico, G., Gaydos, C. A., and Lowenstein, C. J., 2001, Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae, J. Infect. Dis. 183:232–238.
Meier, C. R., Derby, L. E., Jick, S. S., Vasilakis, C., and Jick, H., 1999, Antibiotics and risk of subsequent first-time acute myocardial infarction, JAMA 281:427–431.
Jackson, L. A., Smith, N. L., Heckbert, S. R., Grayston, J. T., Siscovick, D. S., and Psaty, B. M., 1999, Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline, Emerg. Infect. Dis. 5:281–284.
Herings, R. M. C., Leufkens, H. G. M., and Vandenbroucke, J. P., 2000, Acute myocardial infarction and prior antibiotic use, JAMA 284:2990–2999.
Muhlestein, J. B., 2000, Chronic infection and coronary artery disease, Med. Clin. N. Am. 84:123–148.
Sander, D., Winbeck, K., Klingelhofer, J., Etgen, T., and Conrad, B., 2002, Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity, Circulation 106:2428–2433.
Wiesli, P., Czerwenka, W., Meniconi, A., Maly, F. E., Hoffmann, U., Vetter, W., and Schulthess, G., 2002, Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial, Circulation 105:2646–2652.
Mosorin, M., Juvonen, J., Biancari, F., Satta, J., Surcel, H. M., Leinonen, M., Saikku, P., and Juvonen, T., 2001, Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebo-controlled pilot study, J. Vasc. Surg. 34:606–610.
Parchure, N., Zouridakis, E. G., and Kaski, J. C., 2002, Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection, Circulation 105:1298–1303.
Gupta, S., Leatham, E. W., Carrington, D., Mendall, M. A., and Kaski, J. C., 1997, Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction, Circulation 96:404–407.
Gurfinkel, E., Bozovich, G., Daroca, A., Beck, E., and Mautner, B., 1997, Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot study. ROXIS Study Group, Lancet 350:404–407.
Gurfinkel, E., Bozovich, G., Beck, E., Testa, E., Livellara, B., and Mautner, B., 1999, Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study, Eur. Heart J. 20:121–127.
Anderson, J. L., Muhlestein, J. B., Carlquist, J., Allen, A., Trehan, S., Nielson, C., Hall, S., Brady, J., Egger, M., Horne, B., and Lim, T., 1999, Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: Elimination of myocardial infection with Chlamydia (ACADEMIC) study, Circulation 99:1540–1547.
Muhlestein, J. B., Anderson, J. L., Carlquist, J. F., Salunkhe, K., Horne, B. D., Pearson, R. R., Bunch, J. T., Allen, A., Trehan, S., and Nielson, C., 2000, Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC Study, Circulation 102:1755–1760.
Neumann, F., Kastrati, A., Miethke, T., Pogatsa-Murray, G., Mehilli, J., Valina, C., Jogethaei, N., da Costa, C. P., Wagner, H., and Schomig, A., 2001, Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial, Lancet 357:2085–2089.
Stone, A. F. M., Mendall, M., Kaski, J.-C., Gupta, S., Camm, J., and Northfield, T., 2001, Antibiotics against Chlamydia pneumoniae and Helicobacter pylori reduce further cardiovascular events in patients with acute coronary syndromes, J. Am. Coll. Cardiol. 37(2A):1A–648A.
Sinisalo, J., Mattila, K., Valtonen, V., Anttonen, O., Juvonen, J., Melin, J., Vuorinen-Markkola, H., and Nieminen, M. S., 2002, The Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome, Circulation 105:1555–1560.
Dunne, M. W., 2000, Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (weekly intervention with Zithromax [azithromycin] for atherosclerosis and its related disorders) trial, J. Infect. Dis. 181(Suppl. 3):S572–S578.
Coletta, A., Thackray, S., Nikitin, N., and Cleland, J. G., 2002, Clinical trials update: Highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL, Eur. J. Heart Failure 4:381–388.
Cercek, B., Shah, P. K., Noc, M., Zahger, D., Zeymer, U., Matetzky, S., Maurer, G., Mahrer, P., and AZACS Investigators, 2003, Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: A randomised controlled trial, Lancet 361:809–813.
Jackson, L. A., 2000, Description and status of the azithromycin and coronary events study (ACES), J.Infect. Dis. 181(Suppl. 3):S579–S581.
Gieffers, J., Füüllgraf, H., Jahn, J., Klinger, M., Dalhoff, K., Katus, H. A., Solbach, W., and Maass, M., Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment, Circulation 103:351–356.
Bin, X. X., Wolf, K., Schaffner, T., and Malinverni, R., 2000, Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice, Antimicrob. Agents Chemother. 44:1761–1764.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Muhlestein, J.B. (2005). Antiinfective Trials for the Treatment of Chlamydia pneumoniae in Coronary Artery Disease. In: Friedman, H., Yamamoto, Y., Bendinelli, M. (eds) Chlamydia pneumoniae Infection and Disease. Infectious Agents and Pathogenesis. Springer, Boston, MA. https://doi.org/10.1007/0-306-48741-1_12
Download citation
DOI: https://doi.org/10.1007/0-306-48741-1_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-48487-2
Online ISBN: 978-0-306-48741-5
eBook Packages: Springer Book Archive